Press Release
Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
–News Direct–
By Jeremy Golden, Benzinga

Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.
Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.
Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.
Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.
Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.
CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.
Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.
CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).
When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:
1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;
2) Favorable changes in the trajectory of tumor progression;
3) Decreased tumor size of target lesions in most patients; and
4) Reduced size of uninjected tumor lesions.
The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.
As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.
When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.
In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.
In the upcoming year, Candel plans to announce data readouts for the following:
1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;
2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;
3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.
Featured photo by National Cancer Institute on Unsplash.
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Aljanae Reynolds
+1 617-916-5445
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267
Candel Therapeutics
COMTEX_453480918/2655/2024-06-07T08:28:02
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Sheryar Shah Predicts Major Decline in Hong Kong Graduate Entry-Level Jobs by 2028
Sheryar Shah, Head of AI Growth at sher.hk, highlights a 55% year-on-year drop in Hong Kong graduate entry-level vacancies — the lowest in five years — as companies adopt AI for routine junior tasks.
Hong Kong S.A.R., 9th Mar 2026 – Sheryar Shah, Head of AI Growth at sher.hk, has drawn attention to a notable trend in Hong Kong’s graduate employment market: full-time entry-level graduate vacancies have fallen by approximately 55% year-on-year — reaching the lowest level recorded in five years — as companies increasingly adopt generative AI and automation tools for routine junior tasks.

“The entry-level pathway that Hong Kong graduates have traditionally relied on is undergoing visible change,” Shah noted. “We are seeing a clear 55% reduction in advertised graduate positions through the public university portals, and AI is already handling many of the basic starter tasks that used to be managed by new hires. Current trends suggest this shift will continue in the coming years.”
Current data indicates ongoing change in the market
Hong Kong’s graduate recruitment environment is showing clear movement:
- Full-time graduate vacancies through the eight public universities declined approximately 55% year-on-year in the most recent reporting period — the lowest figure in five years.
- Generative AI is now commonly used for functions previously assigned to new graduates: basic email drafting, data entry, customer-service responses, simple translation, content generation, junior administrative support, and routine compliance monitoring.
- Surveys of employers from late 2025 into early 2026 show many companies planning continued adjustments to graduate intake, with AI often identified as an alternative for repetitive entry-level work.
Shah points to the 55% drop as evidence of a broader structural shift, supported by international workforce analyses (McKinsey, Goldman Sachs, IMF 2023–2025) that expect continued automation in administrative, clerical, and service-oriented sectors. “When AI reliably performs 70–80% of a junior role’s output at significantly lower cost, the economic rationale for retaining the human equivalent becomes more challenging,” he explained. “Across many Hong Kong businesses, this reasoning is contributing to the changes we observe in traditional graduate entry opportunities.”
A changing job market structure
Shah highlighted an important distinction:
- Overall employment levels in Hong Kong are not expected to decline sharply. New roles will continue to emerge.
- Emerging demand is increasingly focused on positions that require immediate AI fluency combined with specialised human judgment — a combination that most current graduates are not yet fully prepared to meet from day one.
“The graduate entry market is shifting noticeably,” Shah observed. “Premium opportunities now often require AI proficiency from the outset. The large volume of ‘learn-as-you-go’ starter positions that historically served as the bridge is contracting. The middle ground is narrowing.”
This observation comes as Hong Kong experiences a pronounced contraction in graduate employment in recent years, with ongoing youth unemployment pressures and companies placing greater emphasis on AI solutions for routine functions.
(The 55% figure reflects reported year-on-year vacancy data from Hong Kong’s public university job portals. Future developments will depend on upskilling initiatives, economic conditions, and policy responses. The observed direction is consistent with current trends and international analyses.)
Media Contact
Organization: trustbanana
Contact Person: Sher
Website: https://trustbanana.com
Email: Send Email
Country:Hong Kong S.A.R.
Release id:42312
The post Sheryar Shah Predicts Major Decline in Hong Kong Graduate Entry-Level Jobs by 2028 appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Pure Tax Investigations Provides Specialist HMRC Tax Compliance and Disclosure Services Across the UK
Pure Tax Investigations, led by tax specialist Amit Puri, supports individuals and businesses navigating HMRC tax enquiries and voluntary disclosure procedures.

London, United Kingdom, 9th Mar 2026 – Pure Tax Investigations, a specialist firm focused on HMRC tax compliance and voluntary disclosures, continues to assist individuals, entrepreneurs, and businesses across the United Kingdom with tax enquiry and disclosure matters. The firm brings more than two decades of professional experience to each case, helping clients work through complex tax compliance requirements.
Based in the City of London, Pure Tax Investigations regularly contributes commentary and professional insights to leading industry publications. These include Bloomberg Tax, FT Adviser, Accounting Today, AccountingWEB, Tax Insider, Taxation Magazine, and The Negotiator. The firm shares analysis and information to help professionals and the public better understand the tax disclosure and compliance process.
Most recently, Amit Puri authored a piece on crypto tax disclosures, drawing on his experience in the field of tax compliance and voluntary disclosure procedures.
Puri has also been an active speaker at industry events. He previously presented at Accountex in London and is scheduled to present at FAB 2026 at the Birmingham NEC on March 11.
Areas of Practice
Pure Tax Investigations supports clients across several areas of HMRC tax compliance and voluntary disclosure, including:
- HMRC tax enquiry guidance
- Code of Practice 9 (COP9) compliance procedures
- Contractual Disclosure Facility (CDF) voluntary disclosures
- Complex matters benefiting from prior HMRC inspector experience
The firm’s focus is on helping clients understand their tax position and work through disclosure procedures in a structured and compliant manner.
Expert Perspective
“Many individuals and businesses are simply unaware of their options when it comes to making a voluntary tax disclosure. Our role is to guide people through that process clearly and professionally, so they can resolve their tax position with confidence,” said Amit Puri, Founder, Pure Tax Investigations
Background of Amit Puri
Amit Puri brings more than 21 years of experience in tax investigations and disclosures. He spent over a decade as a senior tax inspector with HMRC, including a period as head of the tax disclosures team.
That background gives Puri a grounded understanding of how HMRC approaches enquiries and disclosures, knowledge he now applies in advising clients. He is regularly sought out by individuals looking to address past tax matters and by professional publications seeking industry perspective on tax compliance trends.
About Pure Tax Investigations
Pure Tax Investigations was established to provide specialist advice on HMRC tax matters. Amit Puri has been working in tax investigations for over 21 years and has spent nearly 12 years in private practice advising clients on compliance and disclosure matters.
The firm operates from the City of London and serves clients across the United Kingdom, including individuals and businesses with overseas connections and UK tax obligations.
To learn more, visit https://pure-tax.com/
For any inquiries, call +44 203 757 5669 or send an email to info@pure-tax.com.
For the latest updates, follow Pure Tax Investigations on social media:
Instagram: @pure.tax.investigations
YouTube @AmitPuri-PureTaxInvestigations
LinkedIn @amitpurigt
LinkedIn (Company): https://www.linkedin.com/company/pure-tax/
Media Contact
Organization: Pure Tax Investigations
Contact Person: Mr. Amit Puri
Website: https://pure-tax.com/
Email: Send Email
Contact Number: +442037575669
City: London
Country:United Kingdom
Release id:42303
The post Pure Tax Investigations Provides Specialist HMRC Tax Compliance and Disclosure Services Across the UK appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Elmark Sign Company Elevates Brand Visibility with Expert Custom Signage Solutions
West Chester, Pennsylvania, United States, 9th Mar 2026 — Elmark Sign Company, a leading provider of custom signs, office branding, and vehicle graphics, continues to set the standard for high-impact visual communication with industry-trusted craftsmanship and strategic design expertise. With over 40 years in business and a track record of more than 50,000 completed projects, Elmark reinforces its commitment to helping businesses enhance visibility, strengthen branding, and create memorable customer experiences.
At a time when a standout presence matters more than ever, Elmark delivers tailored signage solutions that help organizations of all sizes—from local small businesses to global corporations—bring their brand messages to life. The company’s comprehensive portfolio includes acrylic panel signs, ADA & Braille signs, carved signs, dimensional letters, LED-illuminated signs, exterior and interior signage, plaques, vehicle wraps, wall and window vinyl, and wayfinding systems.
Approaching each project with a “client first” mindset, the Elmark team provides a high quality customer experience from start to finish. They work closely with clients to understand their goals, challenges, and unique brand identities, delivering customized signage that not only looks exceptional but also performs under real-world conditions.
Unlike generic sign providers, Elmark offers end-to-end project management, including site surveys, permit acquisition, engineering, and installation services. This holistic approach ensures that each sign is not only visually striking but also compliant with local regulations and optimized for maximum impact.
Elmark Sign Company’s portfolio spans industries and applications—from enhancing retail storefronts and corporate environments to transforming vehicle fleets into mobile billboards. With decades of experience, Elmark has earned the trust of clients across the Mid-Atlantic region and beyond, serving markets such as Chester County, Delaware County, Montgomery County, Bucks County, and New Castle County.
In addition to custom signage, Elmark’s professional design services support brand development through thoughtful visual strategy and creative execution. Whether a business needs new branding assets or a refresh of existing signage systems, Elmark’s experts guide each client through a seamless process from concept to completion.
With a legacy built on quality, reliability, and customer satisfaction, Elmark Sign Company continues to champion innovative signage solutions that help organizations increase brand recognition and engage their audiences more effectively than ever before.
About Elmark Sign Company
Elmark Sign Company is the Mid-Atlantic’s premier manufacturer of custom signs, vehicle wraps, and branding graphics. With 40+ years of experience and thousands of happy clients, Elmark delivers creative, high-quality signage solutions backed by exceptional service and a commitment to excellence.
Website: https://www.elmark.com/
Media Contact
Organization: Elmark Sign Company
Contact Person: Matthew Bayley
Website: https://www.elmark.com/
Email: Send Email
Contact Number: +16106920525
Address:307 Westtown Road
City: West Chester
State: Pennsylvania
Country:United States
Release id:42430
The post Elmark Sign Company Elevates Brand Visibility with Expert Custom Signage Solutions appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Sunshine Jewelries Emphasizes Thoughtful Design With Jewelry Made for Real Life, Real Wear, and Everyday Confidence
-
Press Release7 days ago
DeZero Launches the World’s First AI ‘Second Brain’ for Crypto Traders
-
Press Release7 days ago
Alluring Window Expands Professional Somfy Motorized Shade Installations Across New York City
-
Press Release1 week ago
Context Releases 2025 Luxury Fashion Sustainability Benchmark on ESG Disclosures
-
Press Release1 week ago
Sunshine Jewelries Launches a Line Featuring Everyday Staples for Work, Events, and Gifting
-
Press Release7 days ago
A New Chapter Begins: WeTrade Continues Partnership with Phantom Global Racing
-
Press Release6 days ago
Daughter Exposes Family Theft Amid Father’s Alzheimer’s Battle
-
Press Release7 days ago
JET IT Services Launches IT Audit to Help Foreign Companies With Microsoft 365 Network and Connectivity Issues in China
